Article with P. Jeffrey Conn

Seaside Therapeutics has joined hands with the Vanderbilt University Medical Center to discover and develop small molecules targeting neurologic receptors implicated in Fragile X syndrome, autism and other brain development disorders. If successful, this collaboration takes science and medicine one step closer toward treating typical hallmark symptoms of autism-such as learning and memory problems and obsessive-compulsive behavior-with a new drug.

"Fragile X, caused by a mutation on the X chromosome, is the most frequent inherited cause of mental retardation and an identified cause of autism," says Dr. Randall L. Carpenter, president and CEO of Seaside Therapeutics. "Our focus on identifying the molecular pathophysiology of single-gene disorders associated with autism has provided insights for developing targeted therapeutics with the potential to correct or fundamentally alter the course of brain development and function."

Read More: Fragile hope for brain disorders

 

Annual Meeting

Program CoverThe ACNP Annual Meeting is one of the world's leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psychotropic drugs.

ACNP Publications

Program CoverThe College offers a variety of Publications with the latest and most comprehensive research in psychopharmacology and related fields.

Research Discussions

This forum enables discussion of articles that have appeared in Neuropsychopharmacology. It is intended to stimulate scholarly interactions among researchers, and to help educate members of the public who are interested in psychiatric illness.